BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients

by Vandana Singh, Benzinga Editor

July 9, 2021 6:16 AM | 1 min read | Make a Comment

The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma.
The approval covers Kyprolis in combination with dexamethasone for adult patients who have received at least two prior therapies, including a proteasome inhibitor and an immunomodulatory agent.
Kyprolis is licensed to BeiGene Ltd BGNE in China under a strategic collaboration with Amgen Inc AMGN.
The conditional approval was based on results from the Phase 3 trial. Results showed that the overall response rate, the primary endpoint, was 35.8%.
The median progression-free survival (PFS) was 5.6 months.
Related content: Benzinga's Full FDA Calendar
Price Action: AMGN and BGNE shares closed at $244.28 and $320.11, respectively, on Thursday.

Posted In: Biotech News Health Care FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.